In clinical trials, elevated HDL-C levels after cholesteryl ester transfer protein (CETP) inhibitor administration cannot reduce the incidence of cardiovascular events (8), and average high levels of HDL-C are intimately associated with a higher risk of overall stroke, ischemic stroke and hemorrhagic stroke (9). The gene discussed is CETP; the disease is stroke disorder.